Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: An observational study

Journal of Occupational Medicine and Toxicology

Volumn 3, Issue 1, 2008, Pages

  Xanthopoulos, Athanasios ^a   Bauer, Torsten T ^a   Blum, Torsten G ^a   Kollmeier, Jens ^a   Schönfeld, Nicolas ^a   Serke, Monika ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58249110527     PISSN: None     EISSN: 17456673     Source Type: Journal    
DOI: 10.1186/1745-6673-3-34     Document Type: Article

References (23)

1. Chemotherapy in malignant pleural mesothelioma. A review. ST Ong NJ Vogelzang, J Clin Oncol 1996 14 1007 1017 8622005
2. Advances in Malignant Mesothelioma. BWS Robinson RA Lake, The New England Journal of Medicine 2005 353 1591 1603 16221782
3. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. P Ruffie R Feld S Minkin Y Cormier A Boutan-Laroze R Ginsberg J Ayoub FA Shepherd WK Evans A Figueredo, J Clin Oncol 1989 7 1157 1168 2666592
4. Global use of asbestos and the incidence of mesothelioma. A Tossavainen, Int J Occup Environ Health 2004 10 22 25 15070022
5. Malignant mesothelioma 1982: review of 4710 published cases. G Hillerdal, Br J Dis Chest 1983 77 321 343 6357260
6. The asbestos cancer epidemic. J LaDou, Environ Health Perspect 2004 112 285 290 14998741
7. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. GL Ceresoli LD Locati AJ Ferreri C Cozzarini P Passoni G Melloni P Zannini A Bolognesi E Villa, Lung Cancer 2001 34 279 287 11679187
8. The management of malignant pleural mesothelioma; single centre experience in 10 years. T Aziz A Jilaihawi D Prakash, Eur J Cardiothorac Surg 2002 22 298 305 12142203
9. Malignant pleural mesothelioma: a survival study. JC Harvey EH Fleischman AR Kagan OE Streeter, J Surg Oncol 1990 45 40 42 1696337
10. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. P Ellis AM Davies WK Evans AE Haynes NS Lloyd, J Thorac Oncol 2006 1 591 601 17409924
11. Gemcitabine: current status of phase I and II trials. SB Kaye, J Clin Oncol 1994 12 1527 1531 8040662
12. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). B Lund PE Kristjansen HH Hansen, Cancer Treat Rev 1993 19 45 55 8431926
13. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. RP Abratt WR Bezwoda G Falkson L Goedhals D Hacking TA Rugg, J Clin Oncol 1994 12 1535 1540 8040664
14. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. Y Becouarn M Ychou M Ducreux C Borel F Bertheault-Cvitkovic JF Seitz S Nasca TD Nguyen B Paillot JL Raoul, J Clin Oncol 1998 16 2739 2744 9704726
15. New platinum complexes with anti-tumour activity. TA Connors M Jones WC Ross PD Braddock AR Khokhar ML Tobe, Chem Biol Interact 1972 5 415 424 4652593
16. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. A de Gramont A Figer M Seymour M Homerin A Hmissi J Cassidy C Boni H Cortes-Funes A Cervantes G Freyer, J Clin Oncol 2000 18 2938 2947 10944126
17. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. W Schutte T Blankenburg K Lauerwald J Schreiber I Bork B Wollscgkaeger D Treutler CP Schneider R Bonner, Clin Lung Cancer 2003 4 294 297 14609447
18. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij GM Van AT van Oosterom MC Christian, J Natl Cancer Inst 2000 92 205 216 10655437
19. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. NJ Vogelzang JJ Rusthoven J Symanowski C Denham E Kaukel P Ruffie U Gatzemeier M Boyer S Emri C Manegold, J Clin Oncol 2003 21 2636 2644 12860938
20. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Jassem R Ramlau A Santoro W Schuette A Chemaissani S Hong J Blatter S Adachi A Hanauske C Manegold, J Clin Oncol 2008 26 1698 1704 18375898
21. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. C Manegold J Symanowski U Gatzemeier M Reck PJ von C Kortsik K Nackaerts P Lianes NJ Vogelzang, Ann Oncol 2005 16 923 927 15824080
22. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. C Porta M Zimatore L Bonomi I Imarisio C Paglino A Sartore-Bianchi L Mutti, Lung Cancer 2005 48 429 434 15893013
23. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. K Fizazi H Doubre CT Le A Riviere J Viala C Daniel L Robert P Barthelemy A Fandi P Ruffie, J Clin Oncol 2003 21 349 354 12525529